Effects of primary chemotherapy on biological parameters of locally advanced breast cancer.
Collecchi
P
P
Institute of Pathology, University of Pisa, Italy.
Giannessi
P G
PG
Baldini
E
E
Naccarato
A G
AG
Passoni
A
A
Bevilacqua
G
G
Conte
P F
PF
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000378:metabolism*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D002945:Cisplatin / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D015251:Epirubicin / Q000008:administration & dosage; D005069:Evaluation Studies as Topic; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000627:therapeutic use*; D006801:Humans; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D011446:Prospective Studies; D011518:Proto-Oncogene Proteins / Q000378:metabolism*; D019253:Proto-Oncogene Proteins c-bcl-2; D017526:Receptor, IGF Type 1 / Q000378:metabolism*; D013936:Thymidine / Q000378:metabolism*; D016896:Treatment Outcome; D014316:Tritium
D014408:Biomarkers, Tumor; D011518:Proto-Oncogene Proteins; D019253:Proto-Oncogene Proteins c-bcl-2; D014316:Tritium; D015251:Epirubicin; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D003520:Cyclophosphamide; D017526:Receptor, IGF Type 1; D002945:Cisplatin; D005472:Fluorouracil; D013936:Thymidine; D008727:Methotrexate